The Weekly Term Sheet (2026-W22)

The week in numbers

Disclosed cash and committed capital first. The milestone-inclusive "up to" ceilings are noted second, not led with: where an upfront or a committed amount is disclosed, that is the number to anchor on.

• $650M upfront: Pfizer to Innovent on signing of the global oncology license. Ceiling up to ~$10.5B with milestones, plus up to double-digit royalties to Innovent.
• ~$319.4M raised: Editas underwritten equity offering.
• ~$100M raised: Nanobiotix follow-on (over-allotment exercised).
• ~$100M committed at signing: Apogee / Blackstone royalty-plus-debt package; only the signing royalty tranche is committed now, the rest is milestone-gated or drawable. Ceiling up to ~$1.3B.
• ~$50M reported: True North minority stake in Embio (size secondary-sourced, not company-confirmed).
• $30M, milestone-gated: OSR Holdings buying the VAXIMM VXM01 IP intra-group; sits within an up-to-$815M license.
• ~$12.6M: Skymap / IMPCL stake sale (traditional medicine, logged for completeness).
• ~$8.8M: Psilera seed extension.
• Upfronts undisclosed: Lilly's three vaccine acquisitions (Curevo, Vaccine Company, LimmaTech) total up to ~$3.83B combined, but each is an undisclosed upfront plus milestones, so the headline is a ceiling, not cash paid.
• Undisclosed terms: Merz / Kvvit (China license); SK bioscience / VECOL (the ~$260M is a Colombian-government program budget over ten years, not consideration to SK); ZBD / Teruisi.
• No new capital: daraxonrasib (Royalty Pharma), sac-TMT (Blackstone), ivonescimab (Summit), and the Cogent GIST NDA acceptance re-rate existing royalty paper without new money; clinical and regulatory items are logged as backdrop.

M&A and major licensing:

• Pfizer / Innovent oncology license (Thu May 28): $650M upfront, up to ~$10.5B with milestones, up to double-digit royalties to Innovent; 12 programs, Greater China retained by Innovent (see BD Origination and Licensing)
• Lilly three-company vaccine acquisition (Tue May 26): up to ~$3.83B combined ceiling, upfronts undisclosed; Curevo (shingles), Vaccine Company (EBV), LimmaTech (bacterial) (see M&A and Restructuring)
• OSR Holdings / VAXIMM VXM01 IP (Wed May 27): $30M, milestone-gated, intra-group royalty centralization, not new external capital (see M&A and Restructuring)
• Skymap / IMPCL stake sale (Tue May 26): ~$12.6M (₹121.01 crore), traditional-medicine asset, logged for completeness (see M&A and Restructuring)

Royalty-bearing license-outs (undisclosed financial terms; upfront + milestones + tiered royalties):

• Merz Therapeutics / Kvvit INBRIJA Greater China license (Tue May 26): exclusive license and collaboration for INBRIJA (levodopa inhalation powder) in mainland China, Hong Kong, Macao; Merz receives upfront, development and commercial milestones, plus tiered supply and royalty arrangements; no manufacturing rights granted
• SK bioscience / VECOL Colombia vaccine localization (Tue May 26): SKYVaricella technology transfer and local-manufacturing license inside a ~$260M Colombian-government 10-year initiative; SK bioscience secures preferential negotiation rights on future vaccines through the facility

Financings and royalty-stream events:

• Apogee Therapeutics / Blackstone Life Sciences up to ~$1.3B synthetic-royalty-plus-debt package (Wed May 27): up to ~$800M synthetic royalty (signing / Phase 3-enrollment / data / approval tranches) plus an up-to-~$500M senior debt facility on zumilokibart (APG777, anti-IL-13), announced alongside positive APEX Part B Phase 2 atopic-dermatitis data; low-to-mid single-digit tiered royalty stepping down with sales and zeroing above $8B annual net sales, 15-year term, change-of-control buyback; framed by Blackstone as the largest royalty financing for a pre-Phase 3 program to date (see Financings)
• Editas Medicine ~$319.4M underwritten public offering (Tue May 26): common stock / pre-funded warrants plus accompanying warrants whose expiry is contingent on EDIT-401 Phase 1 LDL-C data; a clinical-catalyst trigger embedded in the equity stack rather than the royalty stack (see Financings)
• Nanobiotix ~$100M global follow-on closing (Tue May 26): over-allotment fully exercised; ~10% of net proceeds earmarked for JNJ-1900, the J&J-partnered radioenhancer carrying alliance milestone/royalty mechanics (see Financings)
• True North / Embio Ltd ~$50M minority investment (Wed May 27): Indian PE firm True North took a minority stake (reported ~$50M for ~25%) in Embio, an India-based maker of APIs via synthetic biology and precision fermentation for regulated markets; third deal of True North's Fund VII and its first pharma investment from that vehicle; Avendus advised Embio (see Financings)
• BLEEDnFIRE Therapeutics launch, non-dilutive grant funding (Wed May 27): Bern-based RNA-therapeutics startup co-founded with the University of Bern, Inselspital and Landmark BioVentures AG launched on non-dilutive grants (Innosuisse, Venture Kick, Gebert Rüf Innobooster, Kickfund) to advance BnF-001, a GalNAc-siRNA targeting protein S (PROS1) across rare bleeding disorders; pre-clinical, no disclosed dollar figure or royalty structure, logged as a Swiss origination data point (see Financings)
• M2care / ZEISS Ventures / Maculaser Oy investment, undisclosed (Thu May 28): European healthtech venture studio M2care (Mérieux Développement / CEA Investissement) and ZEISS Ventures backed Finland-based Maculaser, a temperature-controlled retinal-laser medtech for AMD/DME/CSC; undisclosed amount, board seats to both investors, no royalty structure; medtech VC logged for completeness (see Financings)
• LEQEMBI subcutaneous (lecanemab) PDUFA extended three months to Aug 24, 2026 (original target Sun May 24): shifts a milestone trigger on the BioArctic tiered lecanemab royalty by one quarter (see Regulatory Events)
• Psilera ~$8.8M oversubscribed seed extension (Thu May 28): a syndicate-led Series Seed extension to push neuroplastogen PSIL-006 toward first-in-human trials in alcohol use disorder in 2027; stacks on an up-to-$2M NIH/NIAAA milestone-driven SBIR grant and a Feb 2025 royalty-bearing out-license of Psilera's DMT patent portfolio to atai/AtaiBeckley; ~$13.3M mobilized across equity and grant sources (see Financings)
• Revolution Medicines daraxonrasib (RASolute 302), Royalty Pharma synthetic royalty re-rating (ASCO; data in-window, plenary Sun May 31): positive Phase 3 OS in metastatic pancreatic cancer de-risks Royalty Pharma's up-to-$1.25B synthetic royalty (plus up-to-$750M senior loan) on daraxonrasib; second tranche already triggered, lifting RPRX's first-tier royalty to 4.55% (up to 7.80% if fully drawn) (see Clinical Readouts and Royalty-Aggregator Activity)
• Merck / Kelun-Biotech sac-TMT (OptiTROP-Lung05), Blackstone royalty re-rating (ASCO oral, May 29 – June 2): a 65% progression/death-risk reduction versus Keytruda alone in 1L PD-L1+ NSCLC de-risks the broader sac-TMT program underpinning Blackstone's $700M low-to-mid single-digit royalty (royalty trigger is US 1L TNBC via TroFuse-011) (see Clinical Readouts and Royalty-Aggregator Activity)
• Akeso / Summit ivonescimab (HARMONi-6), Summit ex-China license re-rating (ASCO plenary Sun May 31): OS selected for the ASCO plenary in 1L squamous NSCLC; a positive readout re-rates Summit's ex-China ivonescimab license (upfront + milestones + royalties to Akeso); OS magnitude pending late-breaking release (see Clinical Readouts)
• Cogent Biosciences bezuclastinib GIST NDA accepted, Priority Review (Thu May 28): NDA accepted with Priority Review, PDUFA Nov 30, 2026, no advisory committee; re-rates the Plexxikon / Daiichi Sankyo mid-to-high-single-digit royalty plus milestone stack on bezuclastinib; full Phase 3 PEAK data in an ASCO oral on Sat May 30 (see Regulatory Events)

Other in-window prints:

• Zymeworks zanidatamab HERIZON-GEA-01 Phase 3 NEJM publication (Wed May 27): NEJM published the first-line HER2+ GEA Phase 3 results for Ziihera (zanidatamab) plus chemotherapy ± Tevimbra (tislelizumab), median OS 26.4 months in the triplet vs 19.2 months control; an sBLA is under FDA Real-Time Oncology Review. Directly re-rates the Zymeworks (ZYME) royalty stack, including the $250M RPRX non-recourse royalty-backed note on 30% of Zymeworks' Ziihera royalties from Jazz and BeOne (March 2, 2026) (see Clinical Readouts)
• Junshi Biosciences toripalimab perioperative NSCLC Phase 3 final analysis (Tue May 26 / Wed May 27 wire): NEOTORCH (NCT04158440) final analysis met EFS and MPR efficacy boundaries in resectable Stage II–III NSCLC, expanding the addressable population beyond the prior Stage IIIA–IIIB China approval; touches the Coherus LOQTORZI US/Canada royalty stack and ex-China partner economics (see Clinical Readouts)
• Autobahn Therapeutics FDA Fast Track for elunetirom (ABX-002) (Tue May 26): CNS-selective TRβ-agonist prodrug for adjunctive bipolar I/II depression; private-company designation with no disclosed partner or royalty structure, logged as a CNS expedited-pathway comp (see Regulatory Events)
• ZBD Pharmaceutical / Zhejiang Teruisi TRS005 distribution (Tue May 26): domestic-China distribution contract for the CD20-targeting ADC TRS005 (Phase 2 NHL); related-party (ZBD is a ~16.7% Teruisi shareholder since 2021); terms not disclosed in English-language press
• NMPA approval, "Lilin" (domestic-China 26S proteasome inhibitor) (Mon May 25): registration for multiple myeloma and mantle cell lymphoma; English-language sourcing limited (see caveat)
• Cardior Pharmaceuticals full integration into Novo Nordisk (effective Jun 1, 2026): closing step of the 2024 up-to-€1.025B (~$1.11B) acquisition; corporate milestone, not a new transaction; excluded from totals (see Corporate and Structural)
• Mabgeek MG-K10 (comekibart) Phase III prurigo nodularis topline (Fri May 29): the long-acting anti-IL-4Rα mAb met its primary endpoint; a pure clinical readout with no new transaction. MG-K10 is already partnered to China Medical System (00867.HK) under a Jan 2025 collaboration (co-development ex-AD plus Greater China and Singapore commercialization); economics are indirect, not a tradable royalty. Logged as backdrop, not a deal
• Adrabetadex (Beren Therapeutics / Mandos) Niemann-Pick Type C NDA review extension (Thu May 28): FDA extended the review three months to a Nov 17, 2026 target after classifying the sponsor's information response as a major amendment; pure regulatory action, no royalty or monetization. Logged as regulatory backdrop (see Regulatory Events)
• Imfinzi (durvalumab) plus BCG approved in BCG-naïve high-risk NMIBC (Thu May 28): FDA approved the first immunotherapy combination in NMIBC (sBLA, Phase 3 POTOMAC); durvalumab is AstraZeneca/MedImmune-owned with no identified external tradable royalty holder. Logged as regulatory backdrop (see Regulatory Events)

Excluded from deal-value totals: the SK bioscience / VECOL ~$260M figure is a Colombian-government program investment over ten years, not consideration to SK bioscience, and is shown for reference. INBRIJA and TRS005 license/distribution terms are undisclosed. The Lilly three-company vaccine package headline (up to ~$3.83B combined) is a milestone-inclusive ceiling with undisclosed upfronts; the largest disclosed upfront in the window is the $650M Pfizer pays Innovent.

How the week reads

• M&A, by count: Lilly's three vaccine acquisitions. Combined up to ~$3.83B in ceilings, upfronts undisclosed. Curevo's amezosvatein is a Shingrix competitor (cross-reference: the HCRx Shingrix royalty position); LimmaTech is a Swiss GlycoVaxyn / GSK spin-out that holds an inbound Valneva royalty on its Shigella S4V program.
• Licensing, by value: Pfizer / Innovent. $650M upfront, up to ~$10.5B with milestones, up to double-digit royalties to Innovent. Merz / Kvvit (China) and SK bioscience / VECOL (Colombia) carry undisclosed terms; the Merz INBRIJA asset traces to the 2024 Acorda 363 sale.
• Financings: one structured deal, two equity raises. Apogee / Blackstone is the structured deal (~$100M committed at signing within an up-to-$1.3B royalty-plus-debt package). Editas (~$319.4M, with an EDIT-401 data-trigger warrant) and Nanobiotix (~$100M) are plain raises.
• Royalty paper: re-rated, not redeployed. No new aggregator capital after Apogee. ASCO data (daraxonrasib, sac-TMT, ivonescimab) and the Cogent GIST NDA touch existing Royalty Pharma, Blackstone, and Summit positions without new money.

---

M&A and Restructuring

Three M&A and restructuring events in the cut, all in the front half: Lilly's three simultaneous vaccine acquisitions (Curevo, Vaccine Company, LimmaTech), combined up to ~$3.83B, announced under a single release; the Indian government's approval of the Skymap Pharmaceuticals / IMPCL strategic sale (₹121.01 crore, ~$12.6M), a traditional-medicine asset transfer logged for completeness; and the OSR Holdings / VAXIMM VXM01 IP acquisition ($30M, intra-group IP centralization with a downstream-royalty structuring purpose).

Eli Lilly / Three Vaccine Acquisitions (Curevo, Vaccine Company, LimmaTech): Combined Up to ~$3.83B (Tue May 26)

Eli Lilly and Company (NYSE: LLY) announced agreements to acquire three clinical- and preclinical-stage vaccine companies to expand into infectious disease: Curevo Inc., Vaccine Company, Inc., and LimmaTech Biologics AG (Lilly release). Combined potential consideration is up to ~$3.83B in cash, each transaction inclusive of an upfront payment plus milestone-based payments (combined deal value; WSJ; Axios). All three are subject to expiration of the Hart-Scott-Rodino waiting period (Lilly release).

Target	Geography	Asset / platform	Lead program	Up to
Curevo Inc.	Bothell / Seattle, WA	Non-mRNA adjuvanted subunit vaccine; SLA-SE (TLR4-agonist) adjuvant	amezosvatein (CRV-101), shingles, Phase 3-ready	~$1.5B
Vaccine Company, Inc.	(US)	In Vivo Nanoparticle (IVN) platform; VLP-like antigen display without VLP manufacturing	Five-antigen EBV candidate, Phase 1-ready	~$1.55B
LimmaTech Biologics AG	Schlieren / Zurich, Switzerland	Self-adjuvanting, multi-antigen platform targeting toxins and superantigens	LTB-SA7, anti-S. aureus, Phase 1	~$780M
			Combined	~$3.83B

Curevo Inc. (shingles; up to ~$1.5B)

Curevo (privately held; Bothell / Seattle, WA; founded 2017) develops amezosvatein (CRV-101), a non-mRNA adjuvanted subunit shingles vaccine targeting glycoprotein E on the varicella-zoster virus (Curevo release; The Pharma Letter / Curevo profile). In a Phase 2 head-to-head against the standard of care (GSK's Shingrix), amezosvatein matched immune response across all primary endpoints and reduced activity-limiting fatigue, chills, and injection-site pain by more than half (Curevo release). Curevo shareholders could receive up to $1.5B in cash, inclusive of an upfront payment and a payment upon a specified milestone (Curevo release). Centerview Partners and J.P. Morgan are financial advisors; Cooley is legal advisor (Curevo release).

• Shingrix cross-reference. Amezosvatein uses an optimized version of the same TLR4-agonist adjuvant proven by Shingrix to be biologically active in shingles vaccination, and the Phase 2 head-to-head matched Shingrix immunogenicity while reducing reactogenicity by more than half (Series B / origination chain). Relevant to the HCRx Shingrix $230M royalty position in the Phase 3 database as a clinical-stage competitor entering Phase 3 under Lilly ownership.
• Upstream origination chain. Amezosvatein carries two pre-existing IP-license layers: the core asset in-licensed from the Mogam Institute (funded by GC Biopharma, South Korea), and the SLA-SE adjuvant from AAHI (Seattle) (Series B / origination chain). Venture base: Series A1 ~$26M (2022), Series B $110M (Mar 2025, Medicxi-led; OrbiMed, HBM Healthcare, Sanofi Ventures, RA Capital, Janus Henderson, Adjuvant Capital, GC Biopharma) (Series B / origination chain).

Vaccine Company, Inc. (EBV; up to ~$1.55B)

Vaccine Company develops In Vivo Nanoparticle (IVN) technologies designed to enable the antigen display associated with virus-like particle vaccines while avoiding traditional VLP manufacturing (Lilly release). The lead program is a five-antigen, Phase 1-ready candidate against Epstein-Barr Virus (EBV) (Lilly release). Shareholders could receive up to $1.55B in cash, inclusive of an upfront payment and payments upon certain clinical and commercial milestones (Lilly release).

• Indication context. Lilly cited evidence linking EBV to multiple sclerosis and several malignancies (Lilly release). No upstream royalty chain disclosed.

LimmaTech Biologics AG (bacterial pathogens; up to ~$780M)

LimmaTech (Schlieren / Zurich, Switzerland; clinical-stage) develops vaccines against bacterial pathogens facing rising antimicrobial resistance, including Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis (LimmaTech release). The proprietary platform is self-adjuvanting and multi-antigen, targeting the toxins and superantigens that drive disease; lead program LTB-SA7 is in Phase 1 against S. aureus, cited as the leading cause of surgical-site infection (LimmaTech release). LimmaTech equity holders could receive up to $780M in cash, inclusive of an upfront payment and clinical/regulatory milestone payments (LimmaTech deal terms). LimmaTech is advised by Moelis & Company UK LLP (financial) and Goodwin Procter and Vischer (legal) (LimmaTech deal terms).

• EU-corridor data point. LimmaTech is a Swiss (Zurich-area) clinical-stage vaccine developer, spun out of GlycoVaxyn after GSK's February 2015 acquisition of GlycoVaxyn (ZoomInfo company profile; Life-Sciences-Germany profile). Its Series A reached $40M, co-led by Adjuvant Capital, AXA IM Alts (now BNP Paribas Asset Management Alts following BNP Paribas's 2025 acquisition of AXA IM; named as such in the Lilly deal release), and the Novo Holdings REPAIR Impact Fund, with later participation from Tenmile (Series A close; Lilly deal release investor list).

LimmaTech royalty stack

The royalty stack is layered and program-specific. The lead asset Lilly is acquiring (LBT-SA7) is in-licensed from a third party, the core platform is owned by GSK, and a separate LimmaTech program (Shigella S4V) is out-licensed to Valneva and generates an inbound royalty stream.

Layer	Asset / IP	Counterparty	LimmaTech position	Terms
Platform	Bioconjugation / glycoengineering platform	GSK (acquired with GlycoVaxyn, Feb 2015)	Exclusive R&D license-back since 2015	Undisclosed
Lead asset (Lilly target)	LBT-SA7 (formerly IBT-V02), S. aureus toxoid vaccine	AbVacc Inc. (Integrated Biotherapeutics spin-out, Rockville MD)	In-licensed Dec 2023; exclusive license + option to acquire full rights post-Phase 1 readout	Undisclosed; upstream non-dilutive funding from NIAID/NIH, CARB-X, Novo Holdings REPAIR
Out-licensed program	Shigella4V (S4V) bioconjugate vaccine	In-licensed from GSK (Jul 2023); out-licensed worldwide to Valneva (Aug 2024)	Inbound royalty + milestone holder	€10M upfront + dev/regulatory/sales milestones + low double-digit royalties to LimmaTech
Platform program	Klebsiella bioconjugate vaccine	GSK-owned	In LimmaTech clinic under GSK collaboration	GSK-owned

• Lead asset (LBT-SA7) carries an upstream AbVacc license. LBT-SA7 is not a GSK bioconjugate; it is a six-valent toxoid vaccine in-licensed from AbVacc Inc. (a spin-out of Integrated Biotherapeutics) in December 2023, under an exclusive license plus an option to acquire full worldwide rights post-Phase 1 readout (AbVacc in-license; LBT-SA7 license option). Financial terms were not disclosed. AbVacc's IBT-V02 program was preclinically developed with NIAID/NIH, CARB-X, and Novo Holdings REPAIR Impact Fund support (REPAIR Fund background; AbVacc pipeline). The LimmaTech Phase 1 (NCT06719219) carried FDA Fast Track designation and a CARB-X award of up to $6.5M (Phase 1 dosing; CARB-X portfolio).
• Platform owned by GSK. LimmaTech's bioconjugation/glycoengineering platform was developed by predecessor GlycoVaxyn and is owned by GSK following the February 2015 acquisition; LimmaTech operates under an exclusive R&D agreement with GSK dating to 2015 (LimmaTech Additional Technologies page; startupticker).
• Inbound royalty stream on Shigella S4V via Valneva. LimmaTech in-licensed the Shigella S4V bioconjugate from GSK in July 2023, then out-licensed worldwide development, manufacturing, and commercialization rights to Valneva (Nasdaq: VALN; Euronext Paris: VLA) in August 2024 for €10M upfront, dev/regulatory/sales milestones, and low double-digit royalties on sales (Valneva license; Valneva license terms; Valneva license). S4V holds FDA Fast Track designation (S4V Fast Track). The Lilly acquisition does not target S4V; the inbound Valneva royalty is a LimmaTech asset whose post-acquisition treatment is not specified in the announcement.
• GSK-owned Klebsiella program in clinic. LimmaTech also runs a GSK-owned Klebsiella bioconjugate candidate in clinical evaluation under the GSK collaboration, alongside the GSK-licensed Shigella program and an undisclosed third program (LimmaTech Additional Technologies page).

Lilly acquisition context

• The three deals follow Lilly's prior platform/asset transactions, including the genetic-medicines set (Verve ~$1B, Orna up to $2.4B, Kelonia $3.25B upfront, Engage Biologics ~$202M in W21), and extend into vaccines / infectious disease (Lilly release).
• Lilly stated it will determine accounting treatment after closing under GAAP, with the transactions reflected in financial results and guidance thereafter (Lilly release).

Skymap Pharmaceuticals / IMPCL: Indian Government Strategic-Sale Approval, ₹121.01 crore (~$12.6M) (Tue May 26)

An inter-ministerial panel approved the strategic sale of the Indian government's stake in Indian Medicines Pharmaceutical Corporation Limited (IMPCL) to Skymap Pharmaceuticals Private Limited (Delhi). Skymap emerged as the highest bidder at ₹121,00,94,400 (₹121.01 crore, ~$12.6M at ~₹95.7/USD), above the reserve price (Business Standard). The disinvestment process began roughly three years earlier, with expressions of interest invited in August 2023 and two financial bids received in January 2026.

Term	Detail
Acquirer	Skymap Pharmaceuticals Pvt. Ltd. (Delhi; private)
Target	Indian Medicines Pharmaceutical Corporation Ltd (IMPCL) (the only central public-sector ayurvedic/unani manufacturer, under the Ministry of AYUSH)
Type	Strategic disinvestment / government stake sale
Value	₹121.01 crore (~$12.6M); above reserve price
Status	Approved by inter-ministerial panel (Finance Ministry); subject to completion
Date	Tue May 26, 2026

• Out of scope for tradable royalty origination. IMPCL manufactures classical ayurvedic, unani, and proprietary ayurvedic formulations supplied to central and state government schemes; this is a traditional-medicine pharma asset transfer, not a Western-pipeline or royalty-bearing transaction. Included for completeness as an in-window pharma strategic sale.
• Sourcing caveat. The deep research cross-check dated this May 27; the Finance Ministry approval and the bulk of same-day coverage carry a May 26 dateline. Advisers and final sale documentation were not disclosed in same-day coverage.

OSR Holdings / VAXIMM: $30M VXM01 IP Acquisition Centralizing a 100%-Downstream-Royalty Position at the Parent (Wed May 27)

OSR Holdings, Inc. (Nasdaq: OSRH) entered a definitive Asset Purchase Agreement with VAXIMM AG, its wholly-owned Swiss subsidiary, to acquire the full global VXM01 intellectual property portfolio and related assets for an aggregate $30M (OSRH release; 8-K exhibit, SEC). VXM01 is a clinical-stage oral immunotherapy targeting VEGFR-2, studied in glioblastoma (GBM) and pancreatic ductal adenocarcinoma (PDAC). The acquired portfolio includes issued and pending patents, manufacturing know-how, process technology, regulatory filings, clinical data, biological materials, and assigned contracts, with patent protection across the US, Canada, Europe, Japan, China, and Korea extending into 2038.

The acquisition is the IP-centralization leg of the broader VXM01 structure announced April 29, 2026: a global exclusive license to BCM Europe AG (BCME) carrying up to $815M in development and commercial milestones, with OSRH retaining 100% of downstream royalty economics after BCME recovers its invested capital plus a preferred-return / CAGR threshold. BCME, OSRH's largest shareholder, pledged its entire OSRH equity stake (~30%) as collateral for the milestone obligations, and OSRH holds a $15M put exercisable at $10.00/share six months after the license effective date.

Term	Detail
Acquirer	OSR Holdings, Inc. (Nasdaq: OSRH; Bellevue, WA)
Seller	VAXIMM AG (Switzerland; wholly-owned OSRH subsidiary)
Asset	VXM01: oral VEGFR-2 immunotherapy (GBM, PDAC); Phase 2
IP purchase price	$30M, payable on first BCME-license milestone (Phase 2 GBM/PDAC completion); voluntary partial prepayment permitted
Patent coverage	US, Canada, Europe, Japan, China, Korea; protection into 2038
License counterparty	BCM Europe AG (BCME), via a dedicated investment vehicle (BCM Decentralized Science Investors I, LP)
License economics	Up to $815M milestones; OSRH retains 100% downstream royalties after BCME cost recovery + preferred return
Collateral	BCME pledged ~30% OSRH equity stake against milestone obligations
Governing law	Switzerland (Canton of Basel)
Date	Wed May 27, 2026

• Why it is a royalty-structure read, not a cash event. No external capital changed hands on May 27: this is an intra-group transfer that moves VXM01 IP from a subsidiary to the parent so that the downstream royalty waterfall (and any future "innovative financing and royalty participation structures" OSRH flags) sits at the OSRH level. The disclosure language, plus the company's earlier "Decentralized Science" vehicle naming and the #Tokenization tag on its own social post, signals intent toward a tokenized or syndicated royalty-participation construct on a small-cap oncology asset, a structurally interesting (if speculative) data point for the synthetic-royalty toolkit.
• Scale and caveats. The $30M price is roughly twice OSRH's ~$16.4M market capitalization against ~$2.6M trailing revenue; the milestone-gated payment and the BCME preferred-return waterfall mean the headline royalty position is deeply contingent on VXM01 reaching Phase 2 completion and beyond. Treat the $815M and "100% royalties" figures as structural ceilings, not expected values.

---

BD Origination and Licensing

The licensing block is led by the Pfizer / Innovent up-to-~$10.5B global oncology collaboration (May 28), the largest BD print of the window. Two further cross-border license-outs in the cut are royalty-bearing with undisclosed financial terms: Merz / Kvvit (INBRIJA into Greater China) and SK bioscience / VECOL (SKYVaricella into Colombia). One domestic-China distribution arrangement (ZBD / Teruisi) is included for completeness.

Pfizer / Innovent Biologics: Up to ~$10.5B Global Oncology Licensing and Collaboration (Thu May 28)

Pfizer (NYSE: PFE) and Innovent Biologics (HKEX: 1801) entered a global strategic collaboration to co-develop a portfolio of oncology medicines (Innovent / Pfizer release; deal coverage). Innovent receives a $650M upfront payment and is eligible for up to $9.85B in development, regulatory and commercial milestones, bringing the total deal value to up to ~$10.5B, plus up to double-digit royalties on net sales of each licensed product if approved (Innovent / Pfizer release). The collaboration spans 12 programs, eight Innovent-originated early-stage assets and four Pfizer-proposed discovery programs, across antibody-drug conjugates with novel payloads and multispecific antibodies (deal coverage). The deal is expected to close in Q3 2026.

Term	Detail
Licensor / originator	Innovent Biologics (HKEX: 1801; Suzhou, China)
Licensee	Pfizer (NYSE: PFE)
Total value	Up to ~$10.5B: $650M upfront + up to $9.85B development/regulatory/commercial milestones
Royalties	Up to double-digit on net sales of each licensed product, payable to Innovent
Scope	12 oncology programs: 8 Innovent-originated early-stage + 4 Pfizer-proposed discovery; ADCs with novel payloads + multispecific antibodies
Development split	Innovent leads through Phase 1; Pfizer leads global development thereafter; US/EU profit-sharing on co-developed programs; Innovent retains Greater China rights
Expected close	Q3 2026
Date	Thu May 28, 2026

• The read for CFC. A royalty-bearing license-out from a Chinese originator to a global pharma, with a disclosed upfront, milestone ladder, and tiered royalty to the originator, the structured-origination archetype CFC tracks. At up to ~$10.5B it is the largest licensing print of the W22 window.
• Structure note. Innovent retains Greater China rights while monetizing global development through Pfizer, keeping a double-digit royalty on ex-China sales; the eight-plus-four split (originated plus proposed-discovery) is a platform-style multi-program construct rather than a single-asset license, which spreads the milestone ladder across a pipeline.
• Sourcing note. Confirm the per-program royalty tiers and the precise profit-share geography against the definitive agreement and Innovent's HKEX disclosure before final publication; the public release discloses aggregate figures and the program count, not asset-level economics.

Merz Therapeutics / Kvvit: Exclusive INBRIJA (levodopa inhalation powder) License for Greater China (Tue May 26)

Merz Therapeutics GmbH (Frankfurt; privately held) and Jiangxi Kvvit Pharmaceutical Co. Ltd. (Ganzhou, China; founded 2021) entered an exclusive license and collaboration agreement for INBRIJA (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of OFF episodes in adult Parkinson's disease patients, in mainland China, Hong Kong, and Macao (Merz / Kvvit release; deal coverage).

Under the agreement, Merz will receive upfront, development, and commercial milestone payments plus tiered supply and royalty arrangements, with no manufacturing rights granted (Merz / Kvvit release). Merz supplies INBRIJA, retains global product-quality responsibility and key regulatory activities, and acts as Overseas Holder of the Drug Registration Certificate; Kvvit leads local development, regulatory submissions, and commercialization as Domestic Responsible Person under a jointly agreed China Development Plan and funds local clinical development (Merz / Kvvit release). Financial terms were not disclosed.

Term	Detail
Licensor	Merz Therapeutics GmbH (Frankfurt; private)
Licensee	Jiangxi Kvvit Pharmaceutical Co. Ltd. (Ganzhou, China; founded 2021)
Asset	INBRIJA (levodopa inhalation powder) + proprietary ARCUS inhalation device
Indication	Intermittent treatment of OFF episodes in adult Parkinson's disease (on levodopa/DDI)
Geography	Mainland China, Hong Kong, Macao
Economics	Upfront + development + commercial milestones + tiered supply and royalty arrangements (undisclosed)
Structure	Merz supplies product, retains global quality + key regulatory + Overseas DRC Holder; Kvvit funds and leads local development/regulatory/commercialization; no manufacturing rights granted
Origination chain	INBRIJA acquired by Merz in the 2024 Acorda Therapeutics Chapter 11 363 sale ($185M, with (F)AMPYRA); ARCUS platform
Date	Tue May 26, 2026

• Royalty structure. Merz receives tiered royalties plus milestones and a supply margin on INBRIJA Greater China sales while retaining manufacturing and global quality control (Merz / Kvvit release).
• Origination chain. INBRIJA and (F)AMPYRA were acquired from Acorda Therapeutics in a court-structured 363 sale valued at $185M in 2024 (Acorda 363 sale close).
• Licensing-direction context. The flow runs from a European specialty operator to a China local partner that funds development, alongside the broader 2026 bidirectional China licensing corridor (BioPharma Dive deals).

SK bioscience / VECOL: SKYVaricella Technology Transfer Inside Colombia's ~$260M Vaccine Localization Initiative (Tue May 26)

SK bioscience (KRX: 302440; Incheon, South Korea) signed a vaccine technology-transfer and local-manufacturing cooperation agreement with VECOL (Colombia's state-owned pharmaceutical company), as part of Colombia's national vaccine localization initiative led jointly by the Ministry of Health and Social Protection, the National Health Institute (INS), and VECOL (SK bioscience release; deal terms; deal coverage).

Colombia will invest $260 million over 10 years to strengthen national vaccine self-sufficiency (deal terms). SK bioscience's proprietary varicella vaccine SKYVaricella is the initial product for technology transfer; SK bioscience provides technology, know-how, product introduction, regulatory and production-operations support, while VECOL oversees facility construction and operation, government licensing, and linkage to the National Immunization Program (SK bioscience release). SK bioscience secures preferential negotiation rights for future vaccines introduced through the facility, including its own and broader products adopted by the Colombian government (deal terms). The agreement follows Colombia's decision to switch all 950,000 NIP varicella doses this year to SKYVaricella, after a roughly four-year vendor review of WHO-prequalified suppliers (deal terms).

Term	Detail
Technology provider	SK bioscience (KRX: 302440; Incheon, South Korea)
Local partner	VECOL (Colombia state-owned pharmaceutical company; president Lucia Ayala)
Program sponsor	Colombia Ministry of Health + National Health Institute (INS) + VECOL
Initial product	SKYVaricella (proprietary varicella vaccine; WHO PQ certified 2019, 2nd globally)
Program scale	~$260M Colombian-government investment over 10 years (not a transaction value to SK bioscience)
SK role	Technology + know-how, product introduction, regulatory + production-operations support
VECOL role	Facility build/operation, government licensing, NIP linkage, public-health coordination
Forward option	SK bioscience preferential negotiation rights on future vaccines through the facility
Date	Tue May 26, 2026

• Structure. Technology-transfer and local-manufacturing license inside a government self-sufficiency program; no drug-royalty or synthetic-royalty structure disclosed (SK bioscience release). SK bioscience holds preferential negotiation rights on future vaccines through the facility (deal terms).
• Procurement context. The Colombian NIP switch to SKYVaricella (950,000 doses) followed a four-year WHO-PQ vendor review (deal terms). SK bioscience has supplied SKYVaricella to Latin America via PAHO tenders since 2022 (BioSpectrum Asia).

ZBD Pharmaceutical / Zhejiang Teruisi: Domestic-China Distribution Contract for TRS005 CD20 ADC (Tue May 26)

Heilongjiang ZBD Pharmaceutical Co., Ltd. signed a distribution contract with Zhejiang Teruisi Pharmaceutical for TRS005, an anti-CD20 / MMAE antibody-drug conjugate in Phase 2 for CD20-positive relapsed/refractory non-Hodgkin lymphoma (including DLBCL) (NCI Drug Dictionary: anti-CD20 ADC TRS005; Synapse TRS-005 profile).

TRS005 is a valine-citrulline-linked anti-CD20 MMAE ADC (DAR ~4.2) that delivers a microtubule-disrupting payload to CD20+ B cells (NCI Drug Dictionary; Google Patents US20210130487A1). It is in pivotal Phase 2 in China (R/R DLBCL), with process-validation (PPQ) batches completed at MabPlex in early 2025 ahead of a planned BLA (PPQ milestone). ZBD is an existing ~16.7% shareholder of Teruisi (CNY 400M of a CNY 860M 2021 private placement) (ZBD shareholding).

Term	Detail
Distributor	Heilongjiang ZBD Pharmaceutical Co., Ltd. (existing ~16.7% Teruisi shareholder since 2021)
Originator	Zhejiang Teruisi Pharmaceutical, Inc. (China; president Dr. Kai Huang)
Asset	TRS005: anti-CD20 / MMAE ADC (vc linker, DAR ~4.2)
Indication	CD20+ relapsed/refractory NHL incl. DLBCL
Stage	Phase 2 (pivotal); PPQ completed at MabPlex Q1 2025; BLA-track
Geography	China (domestic)
Terms	Undisclosed (not in English-language press)
Date	Tue May 26, 2026

• Out of scope for tradable royalty origination; domestic-China related-party distribution. Included for completeness. No disclosed royalty structure, no English-language financial terms, and the counterparties are equity-affiliated (ZBD owns ~16.7% of Teruisi). Relevance is limited to the China-domestic ADC commercialization backdrop.
• Sourcing caveat. Distribution-contract terms were not located in English-language primary or trade press; the transaction is reported via deal-tracking aggregation. Direction and economics unconfirmed.

---

Regulatory Events

Four royalty-relevant or tracked regulatory items in the cut: one domestic-China NMPA approval (limited English-language sourcing), one US PDUFA extension affecting a tracked royalty stream, one US Fast Track designation on a private CNS asset, and one US NDA acceptance that re-rates a contractual royalty (Cogent bezuclastinib). Two further US regulatory actions are logged as backdrop only, with no royalty or transaction relevance: the adrabetadex Niemann-Pick review extension and the Imfinzi NMIBC approval.

NMPA Approves "Lilin" (Domestic-China 26S Proteasome Inhibitor) for Multiple Myeloma and Mantle Cell Lymphoma (Mon May 25)

China's National Medical Products Administration (NMPA) approved Lilin, described as a small-molecule 26S proteasome inhibitor, for the treatment of multiple myeloma and mantle cell lymphoma, via the registration pathway for chemical drugs.

The 26S proteasome inhibitor class (bortezomib / Velcade, carfilzomib / Kyprolis, ixazomib / Ninlaro) is an established backbone of multiple myeloma and mantle cell lymphoma therapy; agents bind the chymotrypsin-like subunit of the 26S proteasome, blocking degradation of pro-apoptotic factors (proteasome inhibitor class).

Term	Detail
Regulator	China NMPA (Registration of Chemical Drugs pathway)
Asset	"Lilin": small-molecule 26S proteasome inhibitor (developer/originator unconfirmed in English-language sourcing)
Indications	Multiple myeloma; mantle cell lymphoma
Class context	Bortezomib / carfilzomib / ixazomib generation; established MM + MCL backbone
Date	Mon May 25, 2026

• Class context. Adds a proteasome-inhibitor option to the China MM/MCL market, where the class competes against and combines with anti-CD38 antibodies (Sarclisa, NMPA-approved Jan 2025) and anti-BCMA ADCs (Blenrep, NMPA-approved April 2026).
• Sourcing caveat. English-language primary and trade-press coverage of the "Lilin" approval, including developer identity and INN, was not located. Transliterated brand name; details to be confirmed against NMPA registration records before final publication.

FDA Extends LEQEMBI Subcutaneous (Lecanemab) Starting-Dose PDUFA by Three Months to August 24, 2026 (original target Sun May 24)

The FDA extended its review of the LEQEMBI (lecanemab-irmb) subcutaneous autoinjector starting-dose sBLA by three months, to a target action date of August 24, 2026, from an original PDUFA target of May 24, 2026; the agency requested additional information that constituted a major amendment to the application (FDA approvals tracker). The subcutaneous maintenance indication was approved in August 2025; the current application covers the weekly subcutaneous starting (induction) dose.

Term	Detail
Regulator	US FDA (sBLA, lecanemab subcutaneous starting dose)
Sponsors	Eisai (lead) / Biogen
Royalty holder	BioArctic AB (STO: BIOA-B): milestones on filings/approvals/sales plus royalties on global lecanemab sales; Nordic co-commercialization rights
Original PDUFA	Sun May 24, 2026
Revised PDUFA	Aug 24, 2026 (three-month extension; major amendment)
Prior approval	Subcutaneous maintenance dosing approved Aug 2025

• BioArctic royalty stack: origin and licensing. Lecanemab (BAN2401) originates from the amyloid-beta Arctic mutation discovered by Prof. Lars Lannfelt at Uppsala University, commercialized via BioArctic (founded 2003 on that research). BioArctic licensed global rights to Eisai under a December 2007 development and commercialization agreement (plus a May 2015 back-up antibody agreement); Eisai brought in Biogen under a March 2014 joint development and commercialization agreement (collaboration history).
• BioArctic economics. BioArctic bears no development costs for lecanemab in Alzheimer's and is entitled to regulatory-filing, approval, and sales milestones plus royalties on global sales, and retains Nordic commercialization rights (BioArctic terms).
• Milestone cadence (data points). A €15M payment on Phase 3 (Clarity AD) start and a €5M payment on EMA filing acceptance (Phase 3 milestone; EMA milestone).
• Royalty-stream timing. The three-month extension shifts the associated milestone trigger and the US launch ramp of the subcutaneous starting dose into Q3 2026.
• Sourcing caveats. The specific royalty percentage on lecanemab is not disclosed in BioArctic primary sourcing; BioArctic confirms only "royalties on global sales" plus milestones. The PDUFA date change is tracked via an FDA-approvals aggregator; confirm against an Eisai or Biogen primary disclosure before final publication.

FDA Grants Fast Track to Elunetirom (ABX-002), a CNS TRβ Agonist, for Adjunctive Bipolar Depression (Tue May 26)

The FDA granted Fast Track designation to Autobahn Therapeutics' elunetirom (ABX-002) for the adjunctive treatment of depressive episodes associated with bipolar I or bipolar II disorder in adults (Autobahn IND background). Elunetirom is an orally administered, brain-penetrant, selective thyroid hormone receptor beta (TRβ) agonist prodrug designed to deliver CNS thyroid hormone effects while limiting peripheral T3-like liabilities; it is in Phase 2 for bipolar depression with a separate Phase 2 (AMPLIFY) in adjunctive major depressive disorder.

Term	Detail
Regulator	US FDA (Fast Track designation)
Sponsor	Autobahn Therapeutics (San Diego; privately held)
Asset	Elunetirom (ABX-002): brain-penetrant selective TRβ-agonist prodrug
Indication	Adjunctive treatment of bipolar I/II depression
Stage	Phase 2 (IND cleared Oct 2024; trial initiated Jan 2025)
Royalty structure	None disclosed; no licensing partner
Date	Tue May 26, 2026

• Why it is logged. No tradable royalty or partner is attached: Autobahn is private, most recently funded via a July 2024 Series C led by Newpath Partners (existing investors include ARCH Venture Partners, Blue Owl Healthcare Opportunities, BVF Partners, Biogen, Bristol Myers Squibb, and Pfizer Ventures) (Autobahn Series C). Relevance is as a CNS expedited-pathway comp and a forward partnering/origination candidate ahead of the Phase 2 readout, not as an in-window transaction.
• Sourcing caveat. Earlier guidance pointed to a 2H 2025 bipolar-depression Phase 2 topline; that readout had not been reported as of May 27, 2026, so the designation is occurring against a still-pending pivotal-stage backdrop.

FDA Accepts Cogent Biosciences Bezuclastinib-plus-Sunitinib GIST NDA with Priority Review, PDUFA Nov 30, 2026 (Thu May 28)

The FDA accepted Cogent Biosciences' (Nasdaq: COGT) New Drug Application for bezuclastinib in combination with sunitinib in patients with gastrointestinal stromal tumors (GIST), granted Priority Review, set a PDUFA target action date of November 30, 2026, and is not planning an advisory committee meeting (Cogent release). The filing rests on the Phase 3 PEAK trial, which showed a median progression-free survival of 16.5 months versus 9.2 months for sunitinib alone (HR=0.50, CI 0.39-0.65, p<0.0001) and an objective response rate of 46% versus 26% (Cogent release). Full PEAK results are scheduled for an oral presentation at ASCO on Saturday, May 30, 2026 (Abstract 11500).

Term	Detail
Regulator	US FDA (NDA accepted, Priority Review; no advisory committee)
Sponsor	Cogent Biosciences (Nasdaq: COGT)
Asset	Bezuclastinib (formerly PLX9486; selective KIT D816V / exon 17 inhibitor) + sunitinib
Indication	Gastrointestinal stromal tumors (GIST)
Pivotal data	Phase 3 PEAK: mPFS 16.5 vs 9.2 mo (HR 0.50, p<0.0001); ORR 46% vs 26%
PDUFA	Nov 30, 2026
ASCO	Full PEAK oral, Sat May 30, 2026 (Abstract 11500)
Date	Thu May 28, 2026

• Royalty-stack cross-reference (the read for CFC). Bezuclastinib is in-licensed from Plexxikon (a Daiichi Sankyo Group company), acquired by Cogent via its July 2020 purchase of Kiq Bio. Plexxikon is eligible for up to ~$7.5M in clinical milestones and up to ~$25M in regulatory milestones, plus mid-to-high single-digit tiered royalties on net sales (Cogent 10-K royalty disclosure). The NDA acceptance with Priority Review, plus the May 30 ASCO oral, materially de-risks that contractual royalty and milestone stream ahead of a potential 2026 approval (deal/asset context).
• Why it is in Regulatory Events, not Financings. No new capital printed: this is a regulatory milestone that re-rates an existing, contractual Plexxikon / Daiichi Sankyo royalty rather than originating new paper.
• Sourcing note. Confirm the exact Plexxikon milestone caps and royalty tiers against Cogent's most recent 10-K and any amended license disclosure before final publication; the figures above reflect the 2022 10-K terms.

Regulatory backdrop (logged, no royalty relevance)

Two further US regulatory actions in the back half are tracked for completeness but carry no royalty, monetization, or transaction angle:

• Adrabetadex (Beren Therapeutics / Mandos) Niemann-Pick Type C NDA review extension (Thu May 28). The FDA extended its review by three months to a target action date of November 17, 2026 (from August 17, 2026) after classifying the sponsor's March 18, 2026 information-request response as a major amendment (Beren release). The cyclodextrin-based therapy's lineage runs through Cyclo Therapeutics and historically the Vtesse / Sucampo program; no royalty stack or monetization is disclosed. Logged as regulatory backdrop only.
• Imfinzi (durvalumab) plus BCG approved in BCG-naïve high-risk NMIBC (Thu May 28). The FDA approved AstraZeneca's durvalumab plus BCG, the first immunotherapy combination in non-muscle-invasive bladder cancer, via sBLA on the Phase 3 POTOMAC trial (disease-free survival HR 0.68; 95% CI 0.50-0.93) (FDA approval; coverage). Durvalumab is AstraZeneca / MedImmune-owned with no identified external tradable royalty holder, so no aggregator royalty stream is affected. Logged as regulatory backdrop only.

---

Corporate and Structural

One corporate-integration milestone in the cut: the full absorption of Cardior Pharmaceuticals into Novo Nordisk, effective June 1, 2026. This is the closing step of a 2024 transaction, not a new deal, and is excluded from window deal-value totals; it is included as an EU RNA-therapeutics integration data point.

Cardior Pharmaceuticals Full Integration into Novo Nordisk (Effective June 1, 2026)

Cardior Pharmaceuticals (Hannover, Germany; RNA-based cardiovascular therapeutics) will be fully integrated into Novo Nordisk effective June 1, 2026, with the standalone corporate identity closing (Cardior integration notice). The underlying acquisition was announced March 25, 2024 and closed Q2 2024, for up to €1.025 billion (~$1.11B), inclusive of an upfront payment plus development and commercial milestones (acquisition terms; Cardior deal terms).

Cardior's lead compound is CDR132L, a synthetic antisense oligonucleotide inhibitor of microRNA-132 (miR-132), evaluated in the Phase 2 HF-REVERT trial (NCT05350969) in patients with reduced left ventricular ejection fraction after myocardial infarction (HF-REVERT Phase 2; Cardior deal terms).

Term	Detail
Acquirer	Novo Nordisk A/S (CPH: NOVO-B; NYSE: NVO)
Target	Cardior Pharmaceuticals GmbH (Hannover, Germany; founded 2016; IMTTS / Hannover Medical School spin-out)
Lead asset	CDR132L: synthetic antisense oligonucleotide miR-132 inhibitor; Phase 2 (HF-REVERT, NCT05350969)
Indication	Heart failure with reduced LVEF post-myocardial infarction
Deal value	Up to €1.025B (~$1.11B): upfront + development and commercial milestones
Announced / closed	Announced Mar 25, 2024; closed Q2 2024
Integration milestone	Full integration effective June 1, 2026
Founders	Dr. Claudia Ulbrich (CEO); Prof. Dr. Dr. Thomas Thum (CSO; IMTTS / Hannover Medical School)

Cardior royalty stack

• Academic-license layer (Hannover Medical School / IMTTS). Cardior was founded in 2016 as a spin-off of the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School, directed by Prof. Thomas Thum, and licensed IMTTS technology to develop its ncRNA programs (IMTTS license background). The miR-132 target and antimiR approach underlying CDR132L originate from MHH/IMTTS research, where Thum has filed 40+ ncRNA patents, several licensed (IMTTS license background). The miR-132 cardiac-stress target was identified at MHH (Wikitia / Cardior, sourcing secondary). Specific royalty / milestone terms of the IMTTS-to-Cardior license are not publicly disclosed; this is the upstream royalty layer that now sits beneath Novo Nordisk post-integration.
• Venture base. Cardior raised an initial ~€15M, then a €64M (~$76M) Series B in August 2021 led by Inkef Capital, with Fund+, Sunstone, Hadean Ventures, Coparion (new) and LSP (now part of EQT), BioMedPartners, Bristol Myers Squibb, and High-Tech Gründerfonds (existing) (Series B; Series B). Bristol Myers Squibb held a strategic position pre-acquisition (Series B participants).
• Companion diagnostic. Cardior CE-marked the CardiorHealth miR-132 plasma PCR kit used in HF-REVERT for target-engagement measurement (CardiorHealth PCR kit).
• EU RNA-therapeutics cross-reference. The Cardior integration (German oligonucleotide platform, ~€1B exit) and the LimmaTech acquisition (Swiss vaccine platform, up to $780M) both register in the same cut as European clinical-stage assets being fully absorbed into large pharma. Both originate from European academic / spin-out roots (Hannover Medical School; GlycoVaxyn / GSK).

---

Financings

Four financings in the cut carry royalty-finance structural features: the Apogee Therapeutics / Blackstone Life Sciences synthetic-royalty-plus-debt package, an Editas Medicine equity raise with a clinical-data-contingent warrant, a Nanobiotix follow-on partly earmarked for a partnered radioenhancer, and the Psilera seed extension, which stacks on a prior royalty-bearing atai out-license. The Editas and Nanobiotix prints landed alongside the 94th EAS Congress (Athens, May 24–27); the Apogee package landed with that company's own APEX Part B Phase 2 readout on May 27. Three further items carry no royalty structure and are logged below for completeness: the True North / Embio minority investment (in-window pharma private equity), the BLEEDnFIRE Therapeutics non-dilutive grant-funded Swiss launch, and the M2care / ZEISS Ventures investment in Maculaser (ophthalmology medtech VC, May 28).

Apogee Therapeutics / Blackstone Life Sciences: Up to ~$1.3B Synthetic Royalty + Senior Debt on Zumilokibart (APG777) (Wed May 27)

Apogee Therapeutics (Nasdaq: APGE) entered a strategic financing with funds managed by Blackstone Life Sciences for up to approximately $1.3B, comprising an up-to-~$800M synthetic royalty and an up-to-~$500M senior debt facility, to fund development and commercialization of zumilokibart (APG777), a half-life-extended anti-IL-13 monoclonal antibody (Apogee 8-K, Exhibit 99.1, SEC). The financing was disclosed the same day as positive APEX Part B Phase 2 data in moderate-to-severe atopic dermatitis (Apogee APEX Part B, Exhibit 99.1, SEC). Blackstone's Kiran Reddy described it as the largest royalty financing for a pre-Phase 3 program to date (Apogee 8-K, SEC). Goldman Sachs was exclusive financial advisor to Apogee; Latham & Watkins was Apogee legal counsel and Ropes & Gray advised Blackstone.

Term	Detail
Issuer	Apogee Therapeutics (Nasdaq: APGE)
Counterparty	Funds managed by Blackstone Life Sciences (~$17B AUM)
Total package	Up to ~$1.3B: up-to-~$800M synthetic royalty + up-to-~$500M senior debt facility
Royalty tranches	Up to ~$400M pre-approval ($100M signing; $100M Phase 3 enrollment completion; $200M positive Phase 3 readout); up to ~$400M post-approval ($250M committed + $150M at Apogee option)
Debt facility	Up to ~$500M senior debt, drawable at mutual consent
Royalty rate / term	Low-to-mid single-digit tiered royalty on worldwide net sales; steps down as sales rise; zero above $8B annual net sales; 15-year term; change-of-control buyback
Asset	Zumilokibart (APG777): half-life-extended anti-IL-13 mAb
Lead indication / stage	Moderate-to-severe atopic dermatitis; Phase 3 initiation 2H 2026; additional Phase 2 programs in asthma, EoE, COPD
Advisors	Goldman Sachs (Apogee financial); Latham & Watkins (Apogee legal); Ropes & Gray (Blackstone legal)
Date	Wed May 27, 2026

• Structural read: the largest pre-Phase 3 royalty financing disclosed to date. The synthetic-royalty leg is gated across four discrete catalysts (signing, Phase 3 enrollment completion, positive Phase 3 readout, FDA approval), converting a pre-pivotal asset into a tranched, milestone-contingent cash-flow instrument with an explicit sales-based step-down and a hard $8B annual-sales royalty cap (Apogee 8-K, SEC). The tranche architecture is portable to other late-Phase 2 assets and resets the ceiling for pre-Phase 3 underwriting by Royalty Pharma, HCRx, Sagard, Oberland, Pharmakon, and RTW.
• Concurrent APEX Part B readout (May 27) triggers the data tranche. Apogee reported that APEX Part B met all primary and secondary endpoints at Week 16 across 346 randomized adults: EASI-75 65.9% vs 23.4% placebo, IGA 0/1 46.0% vs 10.9%, EASI-90 47.4% vs 9.3%, and validated low disease activity 20.6% vs 4.5%, with a class-consistent safety profile; the mid dose was selected for Phase 3 (Apogee APEX Part B, Exhibit 99.1, SEC). This readout is the positive-Phase 2 data event that supports Phase 3 initiation; the $200M positive-Phase-3-readout royalty tranche remains a forward catalyst.
• Sourcing note. Full term-sheet mechanics (debt covenants, exact royalty step-down schedule by sales tier, change-of-control buyback math) sit in the Apogee 8-K filed May 27, 2026 (SEC EDGAR CIK 0001974640); confirm against the filed exhibit before final publication.

Editas Medicine: ~$319.4M Underwritten Public Offering with EDIT-401 Data-Contingent Warrant (priced Tue May 26)

Editas Medicine (Nasdaq: EDIT) priced an underwritten public offering for aggregate gross proceeds of up to approximately $319.4M, announced as a proposed offering and priced the same day (Editas offering). The structure pairs common stock (or pre-funded warrants exercisable at $0.0001) with accompanying common-stock warrants whose expiry is the earlier of (i) 30 days after Editas first publicly announces Phase 1 EDIT-401 data showing at least three patients each with greater than 80% LDL-C reduction from baseline with at least one month of follow-up, or (ii) three years from issuance (Editas preliminary 424B5, SEC). Joint book-running managers were Cantor Fitzgerald and Wells Fargo Securities. Editas separately suspended its $300M ATM facility with TD Cowen the same day, having used $43.9M of it to date (Editas 8-K, SEC). Editas held $123.6M in cash and equivalents at March 31, 2026 (Editas Q1 2026 results).

Term	Detail
Issuer	Editas Medicine (Nasdaq: EDIT)
Size	Up to ~$319.4M gross
Instruments	Common stock or pre-funded warrants ($0.0001 exercise) + accompanying common-stock warrants
Warrant trigger	Expiry on earlier of (i) 30 days after first public EDIT-401 Phase 1 data with ≥3 patients each >80% LDL-C reduction (≥1 month follow-up), or (ii) 3 years
Asset	EDIT-401: in-vivo CRISPR, LDLR upregulation; HeFH; first-in-human targeted later 2026
Book-runners	Cantor Fitzgerald; Wells Fargo Securities
Concurrent	$300M ATM with TD Cowen suspended ($43.9M used to date)
Date	Priced Tue May 26, 2026

• Clinical-catalyst trigger embedded in the equity stack. The accompanying warrant functions as a short-dated call whose life accelerates on a defined EDIT-401 Phase 1 LDL-C readout. The mechanism sits inside the common-equity stack rather than the royalty stack, but is structurally adjacent to milestone-contingent royalty payments (for example the PDUFA/EMA-contingent constructs used by aggregators) and is a candidate template for other pre-commercial in-vivo gene-editing issuers (Editas preliminary 424B5, SEC).
• Sourcing caveat. The final per-share price, share count, and pre-funded-warrant split were not retrievable from indexed sources at the time of writing; the headline figure and the preliminary 424B5 (with placeholder fields) were accessible. Confirm against the final pricing 8-K and final 424B5 before publication.

Nanobiotix: ~$100M Global Follow-On Closing, Over-Allotment Fully Exercised (closed Tue May 26)

Nanobiotix (Euronext: NANO; Nasdaq: NBTX) announced full exercise of the underwriters' over-allotment option from its May 2026 global offering, bringing aggregate gross proceeds to approximately $100M (proceeds detail; offering terms). Underwriters were Jefferies, TD Cowen, and Stifel. The offering was priced at $38.98 per ADS / €33.60 per ordinary share. Approximately 10% of net proceeds is earmarked for advancement of JNJ-1900 (NBTXR3), the J&J-partnered radioenhancer (proceeds detail).

Term	Detail
Issuer	Nanobiotix S.A. (Euronext: NANO; Nasdaq: NBTX; Paris / Cambridge MA)
Size	~$100M gross (incl. base + over-allotment)
Price	$38.98 per ADS / €33.60 per ordinary share
Underwriters	Jefferies; TD Cowen; Stifel
Use of proceeds	~10% of net proceeds earmarked for JNJ-1900 (NBTXR3), the J&J-partnered radioenhancer
Date	Closed Tue May 26, 2026

• JNJ-1900 (NBTXR3) royalty stack. NBTXR3 is a hafnium-oxide-nanoparticle radioenhancer originated by Nanobiotix, with a 2019 MD Anderson clinical research collaboration. Nanobiotix licensed worldwide co-development and commercialization to Janssen (J&J) in July 2023 for $30M upfront (up to $60M near-term including in-kind development support), milestones, and royalties (2023 license terms). A March 2025 amendment shifted Phase 3 funding to J&J and adjusted total milestone potential to approximately $2.6B, with tiered double-digit royalties in the low 10s to low 20s unchanged (amended terms).
• HCRx position cross-reference. In October 2025, Nanobiotix monetized part of this stream to HealthCare Royalty (HCRx) for up to $71M; HCRx receives a capped portion of the J&J milestones and royalties on JNJ-1900 sales payable to Nanobiotix (HCRx monetization). The ~$100M follow-on recapitalizes the Nanobiotix equity line on top of the existing J&J license and HCRx royalty-monetization layers on the same asset.

Psilera: ~$8.8M Oversubscribed Seed Extension for Neuroplastogen PSIL-006 (Thu May 28)

Psilera (Tampa, FL; private; CEO Dr. Chris Witowski) closed an oversubscribed ~$8.8M Series Seed extension led by a syndicate of institutional and strategic investors (individual investors not named) to advance its lead neuroplastogen PSIL-006 toward first-in-human trials in alcohol use disorder, targeted for 2027 (Psilera release; round detail). The round stacks on two prior structured layers: an up-to-$2M milestone-driven NIH/NIAAA SBIR grant (Award R44AA031925) (NIH grant) and a February 2025 out-license of Psilera's DMT patent portfolio to atai / AtaiBeckley that included an upfront payment, development milestones, and royalties on future commercial sales.

Term	Detail
Issuer	Psilera Inc. (Tampa, FL; private)
Round	~$8.8M oversubscribed Series Seed extension; syndicate of institutional and strategic investors
Asset	PSIL-006: neuroplastogen; first-in-human targeted 2027
Indication	Alcohol use disorder
Structured layers	Up-to-$2M milestone-driven NIH/NIAAA SBIR grant (R44AA031925); Feb 2025 atai / AtaiBeckley DMT-portfolio out-license (upfront + milestones + royalties)
Capital mobilized	~$13.3M across equity and grant sources
Date	Thu May 28, 2026

• Why it is logged. Small by deal value, but a venture round paired with a genuine royalty-bearing out-license in the company's recent history: the atai / AtaiBeckley DMT license carries upfront, milestones, and commercial royalties to Psilera, and the NIH SBIR adds a non-dilutive, milestone-gated layer. A clean example of an early-stage issuer stacking grant, equity, and royalty income.
• Sourcing caveat. Round size is confirmed; the atai license dollar terms are undisclosed. Lead investors in the seed extension were not named in the release.

True North / Embio Ltd: ~$50M Minority Investment in a Synthetic-Biology API Maker (Wed May 27)

Indian private equity firm True North took a minority stake in Embio Ltd, an India-based producer of active pharmaceutical ingredients via synthetic biology and precision fermentation for regulated markets (DealStreetAsia). The deal marks the third investment of True North's Fund VII and its first pharma investment from that vehicle; Avendus acted as financial advisor to Embio. Embio operates a manufacturing facility in Maharashtra and serves a customer base spanning 80-plus markets including the US, Europe, Japan, Brazil, Canada, Africa, and the Middle East.

Term	Detail
Investor	True North (Mumbai; private equity / private credit; Fund VII)
Target	Embio Ltd (India; APIs via synthetic biology and precision fermentation, regulated markets)
Type	Minority investment / growth capital
Value	Reported ~$50M for ~$25% stake (size/stake per Economic Times; not confirmed in the same-day company announcement)
Advisor	Avendus (to Embio)
Date	Wed May 27, 2026

• Why it is logged. Not a therapeutics-pipeline or royalty-bearing financing, but an in-window pharma transaction above threshold and a data point on synthetic-biology / fermentation API capacity attracting growth capital. No royalty or milestone structure disclosed.
• Sourcing caveat. The same-day company announcement (via DealStreetAsia) confirmed the investment, advisor, and fund but did not state deal size or stake. The ~$50M / ~25% figures trace to an Economic Times report; an earlier February 2026 report had described talks around ~$45M. Confirm against a primary filing before final publication.

BLEEDnFIRE Therapeutics: Non-Dilutive Grant-Funded Swiss Launch, GalNAc-siRNA Targeting Protein S (Wed May 27)

BLEEDnFIRE Therapeutics, an early-stage Bern-based RNA-therapeutics company, launched on non-dilutive funding from Innosuisse, Venture Kick, the Gebert Rüf Foundation Innobooster program, and Kickfund, to advance its lead program BnF-001 toward clinical-candidate nomination (BLEEDnFIRE launch). BnF-001 is a GalNAc-conjugated siRNA that lowers hepatic protein S (PROS1) to rebalance coagulation and restore thrombin generation across rare bleeding disorders (hemophilia, Von Willebrand disease, Glanzmann thrombasthenia), designed as a once-quarterly subcutaneous therapy; preclinically it showed bleeding-episode prevention plus joint and bone protection. The company is co-founded by Landmark BioVentures AG alongside the University of Bern and Inselspital (Bern University Hospital), with co-founders Raja Prince-Eladnani (CSO), Anne Angelillo-Scherrer, Remo Gamboni, and Zaki Sellam (Landmark BioVentures CEO).

Term	Detail
Company	BLEEDnFIRE Therapeutics (Bern, Switzerland; private; founded with University of Bern, Inselspital, Landmark BioVentures AG)
Asset	BnF-001: GalNAc-siRNA targeting protein S (PROS1)
Indications	Rare bleeding disorders (hemophilia, VWD, Glanzmann thrombasthenia)
Stage	Preclinical, toward clinical-candidate nomination
Funding	Non-dilutive grants: Innosuisse, Venture Kick, Gebert Rüf Innobooster, Kickfund (amounts not individually disclosed)
Royalty structure	None disclosed
Date	Wed May 27, 2026

• Why it is logged. Not a royalty-bearing or tradable-origination event, but a Swiss rare-disease RNA origination at the earliest stage, co-built by a Landmark BioVentures nexus structure, and a candidate to track toward a first priced financing round. Same protein-S-silencing thesis as the established hemophilia-rebalancing class (e.g. antithrombin and protein-S directed approaches); BnF-001's PROS1 mechanism maps to the Bern group's PROS1-inhibition patent family.
• Sourcing caveat. No dollar figure, valuation, or milestone/royalty terms disclosed; grant-stage launch only.

M2care / ZEISS Ventures / Maculaser Oy: Undisclosed Medtech Round for Temperature-Controlled Retinal Laser (Thu May 28)

European healthtech venture studio M2care (founded by Mérieux Développement and CEA Investissement) and ZEISS Ventures announced an undisclosed investment in Maculaser Oy, a Helsinki-based medtech developing a temperature-controlled retinal laser therapy for age-related macular degeneration (AMD), diabetic macular edema (DME), and central serous chorioretinopathy (CSC) (M2care release). The Aalto University spin-out's patented system controls retinal temperature in real time during non-damaging laser treatment to activate retinal heat-shock defenses, aiming at earlier intervention than repeated intravitreal injections. M2care's Florence Thueux and ZEISS Ventures' Mike Gänßler join the Maculaser board; proceeds fund the move toward first-in-human studies.

Term	Detail
Investors	M2care (Mérieux Développement / CEA Investissement; Lyon, Paris, Switzerland) and ZEISS Ventures
Target	Maculaser Oy (Helsinki, Finland; founded 2020; Aalto University spin-out)
Technology	Temperature-controlled, non-damaging retinal laser therapy (AMD, DME, CSC)
Stage	Pre-clinical-validation; advancing toward first-in-human
Value	Undisclosed
Governance	Board seats to M2care (Thueux) and ZEISS Ventures (Gänßler)
Royalty structure	None disclosed
Date	Thu May 28, 2026

• Why it is logged. Medtech (device) VC, not a therapeutics or royalty-bearing transaction, but an in-window European healthtech round logged for completeness and as a backdrop data point on ophthalmology device financing. No royalty or milestone structure disclosed; this deal is present on the M2care site at the URL provided.
• Sourcing caveat. Amount undisclosed; M2care closed a €26M fund in 2025 to seed eight projects across cardiology, dermatology, ophthalmology, and neurology, of which Maculaser is one.

EAS Congress Athens, cardiometabolic data (May 24–27)

The 94th EAS Congress (Athens, May 24–27) hosted the window's cardiometabolic gene-editing readouts. Editas presented EDIT-401 non-human-primate data showing an approximately 90% mean reduction in LDL-C and an approximately 90% mean reduction in Lp(a) after a single dose, with concordant ApoB reductions consistent with LDLR upregulation, and a GLP toxicology interim showing no notable treatment-related liver enzyme elevation at the therapeutic dose (EDIT-401 data). Scribe Therapeutics (private) presented an STX-1150 epigenetic PCSK9-silencing late-breaker from its ELXR platform (Scribe EAS preview).

• Scribe royalty structure, two distinct tracks. Scribe's neurological / neuromuscular in-vivo CRISPR programs are licensed to Eli Lilly subsidiary Prevail Therapeutics under a May 2023 collaboration: $75M upfront (cash plus a convertible-note equity investment), R&D funding, more than $1.5B in aggregate milestones, and low-double-digit tiered royalties, with a Scribe option to co-fund and profit-share on one US program (2023 collaboration terms; second milestone). STX-1150, the PCSK9 cardiometabolic asset presented at EAS, sits in Scribe's wholly-owned cardiovascular / metabolic pipeline and is not part of the Lilly collaboration; it carries no disclosed external partner or royalty counterparty.
• Other Scribe platform licenses. Scribe separately licensed its editing technologies to Sanofi (Sep 2022, $25M upfront, up to $1B milestones, tiered royalties, ex-vivo NK-cell therapies) and to Biogen (ALS), neither of which covers STX-1150 (Scribe / Sanofi and Biogen context).
• Sourcing caveat. Scribe is private and did not issue a same-day press release with the STX-1150 numerical readout; figures require conference-floor confirmation.

Zymeworks zanidatamab HERIZON-GEA-01 Phase 3 NEJM publication, first-line HER2+ GEA (Wed May 27)

Jazz Pharmaceuticals (Nasdaq: JAZZ) and BeOne Medicines announced that the New England Journal of Medicine published the Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) plus chemotherapy, with and without the PD-1 inhibitor Tevimbra (tislelizumab), in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA) (Jazz / NEJM release; BeOne / BioSpace). The triplet reached a median overall survival of 26.4 months, versus 24.4 months for zanidatamab plus chemotherapy and 19.2 months for the trastuzumab-plus-chemotherapy control, with benefit seen even in PD-L1 <1% patients. A zanidatamab sBLA is under FDA Real-Time Oncology Review in this indication. The data was concurrently presented at ASCO 2026 and builds on the ASCO GI late-breaker.

Term	Detail
Originator / royalty holder	Zymeworks Inc. (Nasdaq: ZYME); Ziihera is a Zymeworks-developed bispecific HER2 antibody
Licensees	Jazz Pharmaceuticals (rights ex-Asia) and BeOne Medicines (Asia ex-India/Japan, ANZ)
Asset	Ziihera / zanidatamab (zanidatamab-hrii), bispecific anti-HER2
Event	NEJM publication of HERIZON-GEA-01 Phase 3 (1L HER2+ GEA); median OS 26.4 mo (triplet) vs 19.2 mo control
Regulatory status	sBLA under FDA Real-Time Oncology Review (1L HER2+ GEA)
Date	Wed May 27, 2026

• Royalty-stack cross-reference (the read for CFC). Zymeworks earns tiered royalties on Ziihera sales from both Jazz and BeOne. On March 2, 2026, Royalty Pharma funded Zymeworks $250M via a non-recourse royalty-backed note repaid from 30% of Zymeworks' worldwide tiered Ziihera royalties owed by Jazz and BeOne (RPRX transactions). A positive NEJM publication plus an active RTOR sBLA materially de-risks the GEA label expansion that underpins that royalty-backed note, on top of the already-approved biliary tract cancer indication.
• Why it is here, not in M&A/Financings. No new transaction printed on May 27, this is a peer-reviewed data and regulatory-progress event that re-rates an existing, already-monetized royalty stream, the kind of catalyst that moves the value of paper aggregators already hold rather than creating new origination.
• Sourcing caveat. OS/PFS magnitudes are from the company releases and the NEJM abstract; the full hazard-ratio and subgroup detail sits behind the NEJM paper.

Junshi Biosciences NEOTORCH Phase 3 final analysis, perioperative toripalimab in Stage II–III NSCLC (Tue May 26 / Wed May 27 wire)

Junshi Biosciences (HKEX: 1877; SSE: 688180) reported that the NEOTORCH Phase 3 final analysis (NCT04158440) met its event-free survival (EFS) and major pathological response (MPR) efficacy boundaries for perioperative toripalimab plus platinum-doublet chemotherapy, followed by toripalimab maintenance, in resectable Stage II–III NSCLC (Junshi NEOTORCH final analysis). The result expands the supportable population beyond the prior Stage IIIA–IIIB China approval (which rested on the December 2023 interim), and the company plans an sNDA filing in the near term. Specific hazard ratios and response magnitudes were not disclosed with the boundary-met announcement.

• Coherus LOQTORZI royalty cross-reference. Coherus BioSciences (CHRS) holds exclusive US/Canada rights to toripalimab as LOQTORZI, FDA-approved October 27, 2023 in nasopharyngeal carcinoma on the JUPITER-02 and POLARIS-02 studies. A perioperative-NSCLC label expansion would materially widen the US royalty/sales base, though it would require additional US bridging and a US sNDA that Coherus has not yet filed.
• Ex-China partner economics. Downstream cash-flow lines run through Rxilient Health / Hikma (SE Asia / MENA), Dr. Reddy's (India and 20 further countries), and select LatAm rights, with EMA and MHRA marketing applications already submitted in NPC and ESCC. The toripalimab stack is a tradable Asia-pharma origination with multiple parallel royalty lines; the NEOTORCH final analysis is the catalyst that re-rates the US (Coherus) economics ahead of any perioperative NSCLC filing.
• Sourcing caveats. The Shanghai release carries a May 26 dateline while the GlobeNewswire distribution is dated May 27; the underlying event is the same. Quantitative EFS / MPR magnitudes are pending peer-reviewed or congress disclosure (likely WCLC or ESMO 2026).

ASCO 2026 readouts that re-rate existing aggregator royalty positions (May 29 – June 2)

ASCO 2026 opened at the back of the window (May 29). Three readouts re-rate royalty paper that aggregators already hold, without any new capital deployment. The daraxonrasib and ivonescimab plenary presentations are formally dated Sun May 31, one day past the window edge; abstracts, company commentary, and the Cogent PEAK GIST oral (Sat May 30) fall inside the window. These are tracked here as catalysts that move the value of existing positions, the same treatment applied to the Zymeworks and Junshi entries above.

Revolution Medicines daraxonrasib (RASolute 302): Royalty Pharma synthetic-royalty position de-risked

Revolution Medicines (Nasdaq: RVMD) reported positive Phase 3 RASolute 302 overall-survival data for daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, in previously treated metastatic pancreatic cancer: median OS of 13.2 months versus 6.7 months for chemotherapy, hazard ratio 0.40, p<0.0001 (an approximately 60% reduction in risk of death) (Revolution Medicines release; ASCO plenary detail).

Term	Detail
Originator	Revolution Medicines (Nasdaq: RVMD)
Aggregator	Royalty Pharma (Nasdaq: RPRX), funding agreement dated June 24, 2025
Structure	Up to $1.25B synthetic royalty (five $250M tranches) + up to $750M senior secured term loan (up to $2B total; no equity)
Royalty tiers	Post second-tranche: 4.55% on net sales $0-2B, 2.50% $2-4B, 1.00% $4-8B; rises to 7.80% on $0-2B if the remaining $750M is drawn; 0% above $8B; 15-year term
Asset	Daraxonrasib (RMC-6236): RAS(ON) multi-selective inhibitor
Event	Positive Phase 3 RASolute 302 OS (mOS 13.2 vs 6.7 mo, HR 0.40, p<0.0001), mPDAC
Timing	RASolute 302 topline April 13, 2026; ASCO plenary (LBA5) Sun May 31

• Royalty read. The positive Phase 3 OS confirms the second-tranche trigger and de-risks the largest of Royalty Pharma's RAS(ON)-franchise synthetic-royalty positions (RPRX 8-K; RPRX 8-K filing). The arrangement contains no equity component, and the daraxonrasib synthetic royalty steps up to 7.80% first-tier if RPRX draws the remaining loan capacity.
• Sourcing note. Correct the common misattribution: the RPRX daraxonrasib deal dates to June 2025, not 2024. Confirm any updated tranche draws against RPRX disclosure.

Merck / Kelun-Biotech sac-TMT (OptiTROP-Lung05): Blackstone royalty position de-risked

Merck's sacituzumab tirumotecan (sac-TMT), a TROP2 ADC licensed from Sichuan Kelun-Biotech (HKEX: 6990), plus Keytruda cut the risk of progression or death by 65% versus Keytruda alone in first-line PD-L1-positive NSCLC (p<0.0001), with an objective response rate of 70.2% versus 42%; OS data were immature but trending favorably (ASCO oral, OptiTROP-Lung05; ASCO data preview).

Term	Detail
Originator / licensee	Sichuan Kelun-Biotech (HKEX: 6990) out-licensed to Merck (NYSE: MRK)
Aggregator	Blackstone Life Sciences, R&D funding agreement dated Nov 4, 2025
Structure	$700M from Blackstone to Merck; low-to-mid single-digit royalties on sac-TMT net sales across all approved indications, contingent on US approval in 1L TNBC via TroFuse-011; Merck retains all development/commercial control; Blackstone gets no rights to the drug
Asset	Sac-TMT (sacituzumab tirumotecan): TROP2 ADC
Event	OptiTROP-Lung05: 65% reduction in progression/death risk vs Keytruda alone, 1L PD-L1+ NSCLC, ORR 70.2% vs 42%
Timing	Abstract May 21; ASCO oral (Abstract 8506), May 29 – June 2

• Royalty read. Strong 1L lung data de-risk the broader sac-TMT program underpinning Blackstone's $700M royalty (Merck / Blackstone agreement). Note the royalty trigger is specifically US 1L TNBC (TroFuse-011), so the lung readout strengthens the franchise narrative more than it directly trips the payment condition.

Akeso / Summit ivonescimab (HARMONi-6): Summit ex-China license re-rating pending

Akeso's ivonescimab, a PD-1/VEGF bispecific, had its Phase 3 HARMONi-6 overall-survival result (first-line squamous NSCLC, ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy) selected for the ASCO plenary, the first China-developed asset to earn a plenary slot (ASCO preview; plenary detail).

Term	Detail
Originator	Akeso (HKEX: 9926), HARMONi-6 sponsor (China)
Ex-China licensee	Summit Therapeutics (Nasdaq: SMMT): ex-China rights via Akeso license (upfront + milestones + royalties to Akeso)
Asset	Ivonescimab: PD-1/VEGF bispecific
Event	Phase 3 HARMONi-6 OS selected for ASCO plenary, 1L squamous NSCLC
Timing	Plenary slot Sun May 31; OS magnitude pending late-breaking release

• Royalty read. A positive plenary OS readout re-rates Summit's ex-China ivonescimab economics and Akeso's royalty entitlement (Summit Q1 2026 update). The OS hazard ratio was not public at the time of this cut (late-breaking abstract released the morning of presentation); upgrade to a confirmed re-rating once the plenary data publish.

---

Royalty-Aggregator Activity (May 24 – May 30 cut)

One new royalty-aggregator deployment in the cut: the Apogee Therapeutics / Blackstone Life Sciences synthetic-royalty-plus-debt package (up to ~$1.3B, May 27), the only new aggregator deployment across Royalty Pharma, HCRx, Sagard, Ligand, XOMA, DRI, BVF, Pharmakon, and RTW (Royalty Pharma transactions page, most recent listed deployment March 2, 2026 Zymeworks).

No new aggregator capital printed in the back half; several events touch existing royalty paper. The Zymeworks zanidatamab HERIZON-GEA-01 NEJM publication (May 27) touches the RPRX $250M Ziihera royalty-backed note. The OSR Holdings / VAXIMM VXM01 IP centralization (May 27) consolidates a contingent 100%-downstream-royalty position.

At ASCO 2026, the Revolution Medicines daraxonrasib RASolute 302 OS touches Royalty Pharma's up-to-~$1.25B daraxonrasib synthetic royalty, the Merck / Kelun-Biotech sac-TMT OptiTROP-Lung05 data touch the program under Blackstone's $700M sac-TMT royalty, the Cogent bezuclastinib GIST NDA acceptance touches a Plexxikon / Daiichi Sankyo royalty, and the Akeso / Summit ivonescimab HARMONi-6 plenary (Sun May 31) touches Summit's ex-China license. No biotech IPO pricings located in the US window.

• The remainder of the cut's capital activity sat in M&A, cross-border licensing, follow-on equity, private equity, and venture: Pfizer / Innovent global oncology license (up to ~$10.5B), Lilly three-company vaccine package (combined up to ~$3.83B), Skymap / IMPCL (₹121.01 crore, ~$12.6M), OSR Holdings / VAXIMM VXM01 IP ($30M, intra-group), Merz / Kvvit (China license), SK bioscience / VECOL (LatAm technology transfer), Editas (~$319.4M), Nanobiotix (~$100M), True North / Embio (reported ~$50M), Psilera (~$8.8M seed extension), BLEEDnFIRE (non-dilutive grants), and M2care / ZEISS Ventures / Maculaser (undisclosed medtech). All covered above.
• Royalty Pharma's Q1 update posted May 6; no aggregator 8-K printed between then and the May 27 Apogee / Blackstone package. The next scheduled aggregator-relevant calendar items are BIO 2026 (June 22–25) and the EHA and ASCO data flow.

---

Backdrop and Pipeline Read

94th EAS Congress (Athens, May 24–27)

The European Atherosclerosis Society Congress (Athens, May 24–27) included the cardiometabolic in-vivo gene-editing readouts (Editas EDIT-401; Scribe / Lilly STX-1150) covered under Financings.

ASCO 2026 Annual Meeting (May 29 – June 2, McCormick Place, Chicago)

The meeting opened at the back end of W22 (ASCO Annual Meeting). Late-Breaking Abstracts release at 7 AM CT on the day of presentation. The royalty-relevant readouts are tracked under Clinical Readouts and Royalty-Aggregator Activity above: daraxonrasib RASolute 302 (Royalty Pharma synthetic royalty), sac-TMT OptiTROP-Lung05 (Blackstone royalty; Abstract 8506), the Summit / Akeso HARMONi-6 ivonescimab plenary (Summit ex-China license), and the Cogent PEAK bezuclastinib GIST oral (Abstract 11500, Sat May 30).

The daraxonrasib and ivonescimab plenary slots fall Sun May 31, one day past the window edge. Lilly also presented oncology data including NSCLC studies (Lilly ASCO 2026 PR). The Gilead Trodelvy ASCENT-04 PFS2 LBA was not presented in the window.

---

This Weekly Term Sheet is provided for informational purposes only. It does not constitute investment advice, an offer to sell or a solicitation of an offer to buy any security, or a recommendation regarding any investment. Data and disclosures are sourced from public company filings, press releases, and credible secondary reporting. Capital for Cures AG does not warrant the accuracy or completeness of information presented. Readers are advised to consult primary source documentation before making any investment, partnership, or commercial decision.